OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
May 16, 2022
Pfizer will acquire Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in migraine treatments, for $11.7 billion.
May 13, 2022
Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.
April 27, 2022
GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.
April 22, 2022
Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.
April 15, 2022
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9 billion.
April 11, 2022
Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.
Pfizer plans to acquire ReViral and its respiratory syncytial virus therapeutic candidates to strengthen Pfizer’s capabilities in infectious disease research.
April 08, 2022
Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.
April 06, 2022
Standardization is needed in CAR-T cell therapy development due to its inherent complexity.
April 02, 2022
Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.